罗格列酮对初诊肥胖型2型糖尿病患者纤维蛋白原的影响

目的：观察罗格列酮对初诊肥胖型2型糖尿病患者纤维蛋白原的影响。方法：48例初诊肥胖型2型糖尿病患者在饮食和运动治疗基础上,单用罗格列酮4mg/d,观察治疗12周前后的体重指数（BMI）、收缩压（SBP）,舒张压（DBP）、糖化血红蛋白（HbA1c）、胰岛素抵抗指数（HOMA-IR）、总胆固醇（TC）、甘油三酯（TG）、高密度脂蛋白（HDL）、低密度脂蛋白（LDL）、纤维蛋白原（Fg）的变化。结果：罗格列酮治疗后BMI、HbA1c、HOMA-IR、TC、TG、Fg显著下降。结论：罗格列酮治疗初诊肥胖型2型糖尿病患者除了具有降糖、降脂及增加胰岛素敏感性的作用外,并能显著改善凝血功能,减轻炎症反应。

The effect of rosiglitazone on fibrinogen in obese patients with new diagnosed type 2 diabetes mellitus

Objective:To investigate the changes of fibrinogen(Fg)and the significance in obese patients with new diagnosed type 2 diabetes mellitus after the treatment with rosiglitazone.Methods:Forty eight obese patients with new diagnosed type 2 diabetes mellitus were treated with rosiglitazone(4 mg daily).Body mass index(BMI),systolic blood pressure(SBP),diastolic blood pressure(DBP),glycosylated haemoglobin(HbA1c),HOMA-Insulin resistant index(HOMA-IR),total cholesterol(TC),triglyceride(TG),high density lipoprotein-cholesterol(HDL-C),low density lipoprotein-cholesterol(LDL-C),and Fg were measured before and after treating for 12 weeks.Results:Rosiglitazone resulted in a significant reduction in BMI,HbA1c,HOMA-IR,TC,TG,Fg after 12 weeks.Conclusion:Rosiglitazone could significantly reduce the level of Fg and improve coagulanting function and inflammatory reaction in obese patients with new diagnosed type 2 diabetes mellitus except for the function of depressing blood sugar,serum lipid and enhancing insulin sensitivity.